Skip to main content

Nowadays more and more organizations and governments are starting to acknowledge AMR and act on the problem. A few years ago, the WHO also published the priority pathogen list, which includes 12 pathogens that are (multi-)drug resistant, require long hospitalization, and are generally hard to treat. The goal of this list is to spur R&D into the development of novel treatments, antibiotics, and diagnostics in infectious disease and AMR. Without this incentive (leaving it to market forces alone), advances in the government-funded sector as well as the funded sector are just too slow.  

This incentive is needed, as the return on investment of antibiotic research is generally very low, making governments but also private parties not very keen to invest time and efforts into this field. Because of this, less than 5% of the total venture capital investment in pharma between 2003 and 2015 was for antimicrobial development.  

The notion is that with more global awareness and funds specifically dedicated to AMR research, this necessary field can gain the needed interest and popularity to accelerate the development of novel treatments and ensure AMR preparedness. 

As a company working in this field, we are extremely happy with the increasing awareness, as this will make it easier for us to implement change and help ensure healthcare all over the world. 

Sources/further reading:

Close Menu


Fred Roeskestraat 115
1076 EE Amsterdam

Alexander Fleminglaan 1
2613 AX Delft

T: +31(0)85 073 7100